Granules India advances on receiving USFDA approval for Methocarbamol Tablet

08 May 2018 Evaluate

Granules India is currently trading at Rs. 100.95, up by 0.60 points or 0.60% from its previous closing of Rs. 100.35 on the BSE.

The scrip opened at Rs. 100.25 and has touched a high and low of Rs. 102.45 and Rs. 100.25 respectively. So far 17,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 157.00 on 18-May-2017 and a 52 week low of Rs. 96.50 on 07-May-2018.

Last one week high and low of the scrip stood at Rs. 109.60 and Rs. 96.50 respectively. The current market cap of the company is Rs. 2,562.00 crore.

The promoters holding in the company stood at 44.94%, while Institutions and Non-Institutions held 17.55% and 37.51% respectively.

Granules India has received an approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) filed by it for Methocarbamol Tablet 500 mg and 750 mg. The approved ANDA is the bioequivalent and therapeutically equivalent to Reference Listed Drug (RLD) of Robaxin 500 mg and 750 mg of Auxilium Pharmaceuticals. LLC. The company intends to commercialize this product shortly.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

579.95 15.00 (2.66%)
27-Jan-2026 15:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.95
Dr. Reddys Lab 1239.40
Cipla 1312.60
Zydus Lifesciences 894.35
Lupin 2151.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×